Summary
Abbott Laboratories (ABT) filed an 8-K on January 25, 2012, primarily to announce its financial results for the fourth quarter and full year 2011. The report incorporates a press release containing these results, which is furnished as Exhibit 99.1. Investors should note that Abbott utilizes non-GAAP financial measures, such as net earnings and diluted earnings per share excluding specified items, to provide a clearer view of ongoing business performance. These adjustments account for unusual or unpredictable factors like acquisition costs, asset impairments, and restructuring initiatives. While Abbott's management believes these measures offer valuable insights for investors, they are intended to supplement, not replace, traditional GAAP financial figures.
Key Highlights
- 1Abbott Laboratories announced Q4 and full-year 2011 financial results on January 25, 2012.
- 2The 8-K filing primarily serves to provide access to the Q4 and full-year earnings press release (Exhibit 99.1).
- 3The company employs non-GAAP financial measures, such as earnings per share excluding specified items, to present ongoing business performance.
- 4These non-GAAP measures adjust for items including acquisition-related costs, asset impairments, and restructuring initiatives.
- 5Abbott's management uses these non-GAAP measures to assess business performance and believes they offer useful insights to investors.
- 6Investors are advised to consider these non-GAAP measures alongside, and not as a substitute for, GAAP financial measures.
- 7Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer, signed the report.